Stryker Co. (NYSE:SYK) is Tandem Investment Advisors Inc.’s 8th Largest Position

Tandem Investment Advisors Inc. lifted its position in shares of Stryker Co. (NYSE:SYK) by 8.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 266,041 shares of the medical technology company’s stock after buying an additional 20,199 shares during the period. Stryker comprises 3.6% of Tandem Investment Advisors Inc.’s investment portfolio, making the stock its 8th largest position. Tandem Investment Advisors Inc. owned 0.07% of Stryker worth $96,110,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of SYK. Koshinski Asset Management Inc. purchased a new position in shares of Stryker in the first quarter worth about $795,000. Envestnet Portfolio Solutions Inc. increased its stake in Stryker by 43.1% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 18,491 shares of the medical technology company’s stock worth $6,617,000 after purchasing an additional 5,565 shares during the period. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Stryker by 78.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 133,020 shares of the medical technology company’s stock valued at $45,260,000 after purchasing an additional 58,673 shares during the period. M&G Plc bought a new position in shares of Stryker in the first quarter worth approximately $11,534,000. Finally, OFI Invest Asset Management boosted its stake in shares of Stryker by 3,210.9% during the 2nd quarter. OFI Invest Asset Management now owns 3,344 shares of the medical technology company’s stock valued at $1,062,000 after purchasing an additional 3,243 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 0.2 %

Shares of NYSE:SYK opened at $369.83 on Friday. The stock’s 50-day simple moving average is $360.91 and its two-hundred day simple moving average is $345.12. The stock has a market capitalization of $140.99 billion, a price-to-earnings ratio of 39.64, a PEG ratio of 2.78 and a beta of 0.91. Stryker Co. has a 52-week low of $266.93 and a 52-week high of $376.04. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company had revenue of $5.49 billion for the quarter, compared to the consensus estimate of $5.37 billion. During the same quarter last year, the firm posted $2.46 earnings per share. The firm’s revenue was up 11.9% compared to the same quarter last year. Analysts expect that Stryker Co. will post 12.06 EPS for the current year.

Insider Transactions at Stryker

In other news, insider Viju Menon sold 600 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the sale, the insider now directly owns 9,069 shares in the company, valued at $3,219,495. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Stryker news, VP M Kathryn Fink sold 2,121 shares of Stryker stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $370.00, for a total transaction of $784,770.00. Following the transaction, the vice president now owns 10,042 shares of the company’s stock, valued at $3,715,540. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Viju Menon sold 600 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the transaction, the insider now owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,068 shares of company stock worth $3,693,972 in the last 90 days. 5.90% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Citigroup increased their price objective on Stryker from $406.00 to $411.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Stifel Nicolaus reduced their price objective on shares of Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Truist Financial lifted their target price on shares of Stryker from $370.00 to $380.00 and gave the stock a “hold” rating in a report on Wednesday, October 30th. UBS Group increased their price target on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Finally, StockNews.com lowered shares of Stryker from a “buy” rating to a “hold” rating in a report on Wednesday. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $393.65.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.